The Safety and Efficacy of Low-Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn's Disease, and Other Chronic Pain Disorders

Featured Article: Serum [Met5]-enkephalin levels are reduced in multiple sclerosis and restored by low-dose naltrexone

(2017) Michael D Ludwig et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

Naltrexone Inhibits IL-6 and TNFα Production in Human Immune Cell Subsets following Stimulation with Ligands for Intracellular Toll-Like Receptors

(2017) Rachel Cant et al.   Frontiers in Immunology

Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of toll-like receptor 4

(2016) X Wang et al.   BRITISH JOURNAL OF PHARMACOLOGY

Naltrexone at low doses upregulates a unique gene expression not seen with normal doses: Implications for its use in cancer therapy

(2016) Wai M. Liu et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Multiple sclerosis prevalence in the United States commercially insured population

(2016) Piyameth Dilokthornsakul et al.   NEUROLOGY

A sudden and unprecedented increase in low dose naltrexone (LDN) prescribing in Norway. Patient and prescriber characteristics, and dispense patterns. A drug utilization cohort study

(2016) Guttorm Raknes et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Multiple Chronic Conditions and Use of Complementary and Alternative Medicine Among US Adults: Results From the 2012 National Health Interview Survey

(2016) Laura Falci et al.   Preventing Chronic Disease

Duration of opioid receptor blockade determines biotherapeutic response

(2015) Patricia J. McLaughlin et al.   BIOCHEMICAL PHARMACOLOGY

Fibromyalgia

(2015) Gary W. Jay et al.   DM DISEASE-A-MONTH

Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis

(2015) Leslie A Hammer et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

Low Dose Naltrexone for Treatment of Multiple Sclerosis

(2015) Anthony P. Turel et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain

(2014) Jarred Younger et al.   CLINICAL RHEUMATOLOGY

Modulating the delicate glial–neuronal interactions in neuropathic pain: Promises and potential caveats

(2014) Vinod Tiwari et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A

(2014) Shahram Attarian et al.   Orphanet Journal of Rare Diseases

Off-Label, Low-Dose Naltrexone for Refractory Chronic Low Back Pain

(2014) Babita Ghai et al.   PAIN MEDICINE

Ex vivostudies for the passive transdermal delivery of low-dose naltrexone from a cream; detection of naltrexone and its active metabolite, 6β-naltrexol, using a novel LC Q-ToF MS assay

(2014) Kalliopi Dodou et al.   PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY

Low-dose naltrexone for the treatment of fibromyalgia: Findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels

(2013) Jarred Younger et al.   ARTHRITIS AND RHEUMATISM

Treatment of a relapse-remitting model of multiple sclerosis with opioid growth factor

(2013) Leslie A. Hammer et al.   BRAIN RESEARCH BULLETIN

Opioid growth factor (OGF) for hepatoblastoma: a novel non-toxic treatment

(2012) Moshe Rogosnitzky et al.   INVESTIGATIONAL NEW DRUGS

Is Fibromyalgia An Endocrine/Endorphin Deficit Disorder? Is Low Dose Naltrexone a New Treatment Option?

(2012) Seethalakshmi Ramanathan et al.   PSYCHOSOMATICS

Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis

(2011) Kristen A. Rahn et al.   BRAIN RESEARCH

Therapy with the Opioid Antagonist Naltrexone Promotes Mucosal Healing in Active Crohn’s Disease: A Randomized Placebo-Controlled Trial

(2011) Jill P. Smith et al.   DIGESTIVE DISEASES AND SCIENCES

The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice

(2011) Renee N. Donahue et al.   GYNECOLOGIC ONCOLOGY

Modulation of the opioid growth factor ([Met5]-enkephalin)-opioid growth factor receptor axis: Novel therapies for squamous cell carcinoma of the head and neck

(2011) Patricia J. McLaughlin et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Ascorbic acid in Charcot–Marie–Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial

(2011) Davide Pareyson et al.   LANCET NEUROLOGY

The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial

(2010) Naser Sharafaddinzadeh et al.   Multiple Sclerosis Journal

Evidence that opioids may have toll-like receptor 4 and MD-2 effects

(2009) Mark R. Hutchinson et al.   BRAIN BEHAVIOR AND IMMUNITY

Dependence on Nuclear Localization Signals of the Opioid Growth Factor Receptor in the Regulation of Cell Proliferation

(2009) Fan Cheng et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

Effect of ascorbic acid in patients with Charcot–Marie–Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial

(2009) Joëlle Micallef et al.   LANCET NEUROLOGY

Fibromyalgia Symptoms Are Reduced by Low-Dose Naltrexone: A Pilot Study

(2009) Jarred Younger et al.   PAIN MEDICINE

No NO, no pain? The role of nitric oxide and cGMP in spinal pain processing

(2009) Achim Schmidtko et al.   TRENDS IN NEUROSCIENCES

Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4)

(2008) Mark R. Hutchinson et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Opioids and the treatment of chronic pain: Controversies, current status, and future directions.

(2008) Andrew Rosenblum et al.   EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY

A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis

(2008) M Gironi et al.   Multiple Sclerosis Journal